The Globe and Mail reports in its Thursday, Oct. 5, edition that Stifel analyst Justin Keywood has reaffirmed his "buy" call on Dentalcorp Holdings. The Globe's David Leeder writes that Mr. Keywood trimmed his target by $1 to $15. Analysts on average target the shares at $13.35. Mr. Keywood says in a note: "We update our estimates, showing a moderation of growth expectations with lower M&A contributions, but double-digit growth objectives appear in-tact with 18-per-cent adj. EBITDA margins. Dentalcorp's stock has seen significant pressure, down 34 per cent LTM [last 12 months] and valuation now at 8 times NTM [next 12 month] EBITDA. The pressure includes a 20-per-cent contraction, following the conclusion of a strategic review in May, 2023, to continue operating as the largest public DSO and No. 1 market share leader in Canada. An NCIB was subsequently activated, outlined below but with an insider sale in August. Dentalcorp's balance sheet remains levered at 4.4 times net debt/adj. ... Although, there are several moving parts to consider with an unfavorable market backdrop, we continue to see the business model as defensive with recent supportive dentist feedback and intact fundamental."